


02-Feb-28 15:47

From-GOUDREAU GAGE C

T-518 P.06/07 F-911

COPY OF PAPERS  
ORIGINALLY FILED**COPY**PATENT  
Docket No. 514012000200  
Client Ref. 760/12326.50**RECEIVED**

AUG 22 2002

TECH CENTER 1600/2900

**DECLARATION FOR UTILITY PATENT APPLICATION****AS A BELOW-NAMED INVENTORS, WE HEREBY DECLARE THAT:**

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING ORPHAN NUCLEAR RECEPTOR** ERRalpha, the specification of which was filed on August 8, 2001 as United States Application Serial No. 09/925,720.

**WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.**

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (mm/dd/yyyy)	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/119,024	February 8, 1999

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

02-Feb-28 15:47

From-GOUDREAU GAGE C

T-518 P.07/07 F-911

Application Serial No.	Filing Date	Status
PCT/CA00/00145	February 8, 2000	<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

March 12, 2002

Date

Name: Vincent GIGUERE  
 Residence: 277 Quebec, Outremont, Quebec, H2V 3W1 Canada  
 Citizenship: Canada  
 Post Office Address: Same as above


Date

Name: Robert SLADEK  
 Residence: 3699 Ste-Famille, Montreal, Quebec, H2X 2L5 Canada  
 Citizenship: Canada  
 Post Office Address: Same as above

Date

Name: Jiang-Ming LUO  
 Residence: 1626 North Fig Avenue, Marshfield, Wisconsin 54449  
 Citizenship: United States of America  
 Post Office Address: Same as above

02-EP-16:40/189 From: GOUDREAU GAGE L

COPY OF PAPERS  
ORIGINALLY FILED

PATENT  
Docket No. 514012000200  
Client Ref. 760/12326.50

## DECLARATION FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTORS, WE HEREBY DECLARE THAT:

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING ORPHAN NUCLEAR RECEPTOR** ERRalpha, the specification of which was filed on August 8, 2001 as United States Application Serial No. 09/925,720.

WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (month/year)	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/119,024	February 8, 1999

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

R. -07'02(THU) 11:10 GENOME LAB

03/01/02 VEN 10:55 FAX 514 397 9400

TEL:514 934 53  
BROUILLETTE CHARPENTIER  
+ 12 GBR/GRATION 5--

P.003

Resolved: 2/20/2 3:00PM;

T-816 P.07/07 F-810

02-Feb-20 16:35 FREN-GOUDREAU GAGE DUBIE

Application No. <b>PCT/CA00/00145</b>	File No. <b>February 8, 2000</b>	<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned
---------------------------------------	----------------------------------	---

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Name: **Vincent GUILLEUX**  
 Residence: **271 Quai, Outremont, Quebec, H2V 3W1 Canada**  
 Citizenship: **Canada**  
 Post Office Address: **Same as above**

7 May 2001  
 Date

Rob SLADEK  
 Name: **Robert SLADEK**  
 Residence: **3450 Ste-Foy, Montreal, Quebec, H2X 3L5 Canada**  
 Citizenship: **Canada**  
 Post Office Address: **Same as above**


Date

Name: **Tien-Ming LIO**  
 Residence: **1025 Ward Pk Avenue, Martinsburg, West Virginia 26440**  
 Citizenship: **United States of America**  
 Post Office Address: **Same as above**

02-Feb-28 15:47

From-GOUDREAU GAGE, J.C.

T-518 P.06/07 F-811

COPY OF PAPERS  
ORIGINALLY FILEDPATENT  
Docket No. 514012000200  
Client Ref. 760/12326.50**DECLARATION FOR UTILITY PATENT APPLICATION****AS A BELOW-NAMED INVENTORS, WE HEREBY DECLARE THAT:**

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING ORPHAN NUCLEAR RECEPTOR** ERRalpha, the specification of which was filed on August 8, 2001 as United States Application Serial No. 09/925,720.

**WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.**

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/119,024	February 8, 1999

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

03/01/02 VEN 17:08 FAX 514 387 8465

Received: 2/26/2 3:40PM

02-Feb-28 15:00 Free-COUDREAU GAGE DUBUC

BROUILLETTE CHARPENTIER  
CORPORATION INC.

0008

T-518 P.07/07 F-618

Application Serial No.	Filed Date	Patented	Pending	Abandoned
PCT/CA00/00145	February 8, 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: \_\_\_\_\_  
Name: VINCENT GAGLIARDI  
Residence: 277 Quai des Chateaux, Quebec, H2V 9P7 Canada  
Citizenship: Canada  
Post Office Address: Same as above

Date: \_\_\_\_\_  
Name: ROBERT SLADEK  
Residence: 3459 Ste-Famille, Montreal, Quebec, H3K 2L5 Canada  
Citizenship: Canada  
Post Office Address: Same as above

3-6-02  
Date: \_\_\_\_\_  
Name: LING-MING LUO  
Residence: 1025 North Fitzgerald, Marshfield, Wisconsin 54449  
Citizenship: United States of America  
Post Office Address: Same as above

905 W. CHAPEL ST.

JV